The role of early health economics within implementation science: the case of innovative hearing treatments

Imagine a world where a new medical treatment arrives with the promise of curing a condition that has no cure today. Before a single patient receives it, a critical question must be answered: is this treatment worth the cost? This is the domain of health economics, a field that calculates whether the health benefits of a new drug or device justify the money required to produce and deliver it. At the same time, another group of experts, known as implementation scientists, studies how to get these new treatments into everyday hospitals and clinics so that they actually work for the people who need them. For a long time, these two groups have worked in parallel lanes. The economists build complex models to predict value, often waiting until a treatment is proven to work before asking about the price. The implementation scientists focus on the human and organizational hurdles of adoption, often treating money as a secondary detail or a problem to be solved later. But when a treatment is incredibly expensive and potentially life-changing, waiting until the end to ask about the cost can be too late. The financial reality might block the treatment from ever reaching the patient, regardless of how well it works.

This tension is particularly sharp in the field of hearing loss. Millions of people suffer from sensorineural hearing loss, a type of damage to the inner ear that current devices like hearing aids cannot fully fix. They amplify sound but do not restore the clarity of natural hearing. Now, new therapies, including gene therapies, are entering the clinical stage with the potential to repair the hearing system itself. These treatments are innovative and promising, but they are also likely to be very expensive. A team of researchers from universities in the UK and the Netherlands set out to bridge the gap between the economists and the implementation scientists. They wanted to see if they could combine their methods into a single, unified plan that would guide a new treatment from its earliest days of development all the way to its routine use in hospitals. Their goal was not just to talk about working together, but to build a practical map that shows exactly where and how financial planning and implementation planning should happen at the same time.

The researchers used a known framework called SPRINT, which stands for the Structured Pathway for Real-world ImplemeNTation. Think of SPRINT as a six-step guide that helps organizations take a new idea and make it a normal part of daily work. The steps range from the initial mobilization of resources to the final stage where the new practice is fully accepted and embedded. The team took this existing guide and added a new layer to every single step: the perspective of early health economics. They called this new combined framework ECONO-SPRINT. To test if this idea worked, they looked back at two specific studies they had already conducted on innovative hearing treatments. These studies were unique because they were done before the treatments were fully proven or priced, relying on expert opinions and simulations to predict how the treatments might perform. By mapping these past studies onto the six steps of the SPRINT guide, the researchers could see exactly where economic questions and implementation tasks overlapped.

In the first stage, which is about getting ready and mobilizing support, the researchers found that economic modeling is not just a calculation but a way to bring people together. Before a treatment is even built, creating a model forces developers, doctors, and government officials to agree on what the treatment is supposed to do and who it is for. This process helps identify the biggest barriers to adoption early on. As the plan moves to the second stage, fitting the treatment into the current hospital setting, the researchers showed that economic tools can determine if a treatment is actually viable. They used a method called "headroom analysis" to calculate the maximum amount of money a new treatment could cost while still being considered a good value for the health system. This analysis revealed that for hearing loss, there is a significant amount of room for improvement in current care, meaning a new treatment could offer real value. However, they also found that this value depends heavily on specific details, such as how severe the hearing loss is in the patients being treated. If the treatment only helps a small group of people, or if the recovery is only partial, the financial value drops sharply.

The third stage focuses on getting staff and leaders to buy into the change. Here, the researchers demonstrated that early economic evidence can be a powerful tool for persuasion. By showing leaders exactly how much money a new treatment could save the system in the long run, or how it could improve patient lives, they can overcome the natural hesitation to spend money on unproven ideas. The models can show the range of possible outcomes, giving leaders a clear picture of the risks and rewards. In the fourth stage, which involves training staff and enabling action, the researchers identified a gap. While economic models are great at predicting the cost of the drug itself, they often ignore the cost of teaching doctors and nurses how to use it. The team noted that this "learning curve" is a real cost that needs to be planned for, but it is frequently left out of early financial plans. They suggested that future models must include the cost of training and the temporary slowdown in efficiency that happens while staff learn the new system.

As the process moves into the fifth stage, where the team learns from real-world use and adjusts the plan, the economic models become dynamic. Instead of being a static prediction, the model is updated with real data as it becomes available. If the treatment works better than expected, the model changes. If it is more expensive, the model adjusts. This allows decision-makers to see if the treatment is still worth the investment as time goes on. Finally, in the sixth stage, where the treatment becomes a normal part of practice, the focus shifts to confirming that the treatment is affordable for the health system to fund permanently. The researchers highlighted a critical problem: a treatment might be "cost-effective" in a general sense, meaning it provides good value for money, but still be too expensive for a specific hospital or region to afford all at once. This gap between value and affordability is a major hurdle. The ECONO-SPRINT framework suggests that payment strategies, such as paying only if the treatment works or spreading the cost over time, need to be discussed early, long before the treatment is officially approved.

The paper concludes that by integrating these two fields, stakeholders can avoid the common trap of discovering that a treatment is too expensive only after it has been developed and tested. The ECONO-SPRINT framework offers a shared language for developers, doctors, and policymakers to plan for the future together. It suggests that for high-cost, potentially curative innovations like gene therapies for hearing loss, the financial and practical sides of adoption must be woven together from the very beginning. While the framework was built using hearing treatments as an example, the researchers believe it can be applied to any new medical breakthrough that faces the same difficult balance between being a good value and being affordable. The work does not claim to have solved the problem of funding new medicines, but it provides a clear, structured way to start the conversation earlier and more honestly, ensuring that when a miracle treatment arrives, the system is ready to welcome it.